Table 2. Prostate profile.
| Variable | Control | Testosterone treatment | |||
|---|---|---|---|---|---|
| BPH | CO (0.075 mg/kg) | DCL (0.075 mg/kg) | Finasteride (0.8 mg/kg) | ||
| Prostate weight (g) | 1.09±0.10 | 1.87±0.17a | 1.40±0.22b | 1.66±0.16 | 1.42±0.07b |
| Prostate index (%) | 0.22±0.02 | 0.45±0.04a | 0.32±0.05b | 0.40±0.05 | 0.34±0.02b |
| Prostate volume (mm3) | 2,589±576 | 6,471±456a | 4,135±679b | 5,399±790 | 4,084±437b |
Values are presented as mean±standard error of the mean (n=6). A rat model of benign prostate hyperplasia (BPH) was induced with daily injections of 5 mg/kg testosterone for 16 weeks after castration; then, 0.075 mg/kg costunolide (CO), 0.075 mg/kg dehydrocostus lactone (DCL), or 0.8 mg/kg finasteride was administered orally to the rats for 8 weeks after induction. Prostate weight and prostate index ‘prostate weight (g)/body weight (g)×100’ were calculated, and prostate volume was measured using a digital caliper (mm3).
ap<0.001 compared to the control group; bp<0.001 compared to the BPH group. Statistical analyses were conducted using ANOVA and Dunnett's multiple comparison test.